We are 212,287 members in 82 forums discussing 151,850 topics.

Help with Abbreviations

Topic: The CONTESSA study is enrolling! Advanced-stage, HR+, HER2-

Forum: Stage IV and Metastatic Breast Cancer ONLY —

A place for those managing the ups & downs of a Stage IV/metastatic breast cancer diagnosis. Please respect that this forum is for Stage IV members only. There is a separate forum For Family and Caregivers of People with a STAGE IV Diagnosis.

Posted on: Jun 1, 2018 03:28PM - edited Jun 2, 2018 11:00AM by Moderators

Moderators wrote:

The CONTESSA study is looking to see if tesetaxel, an experimental taxane chemotherapy medicine that is taken orally as a pill, in combination with a lower-than-usual dose of Xeloda (chemical name: capecitabine) is better than the standard dose of Xeloda alone. Xeloda also is taken orally as a pill.

The CONTESSA study is being conducted at multiple sites around the world, including in the United States, the United Kingdom, Australia, France, Germany, Italy, Spain, and Russia.

For more information or to enroll, visit the CONTESSA Trial page on Breastcancer.org:http://www.breastcancer.org/treatment/clinical_trials/featured/contessa.

People are eligible to participate in the CONTESSA trial if they:

  • have been diagnosed with hormone-receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
  • were treated with a taxane before or after breast cancer surgery for an earlier stage of breast cancer
  • were treated with any number of hormonal therapy medicines
  • were treated with any number of targeted therapy medicines, such as Ibrance (chemical name: palbociclib) or Afinitor (chemical name: everolimus)
  • have received no chemotherapy to treat the locally-advanced or metastatic disease
    OR received one chemotherapy regimen that did not include a taxane or Xeloda to treat the locally advanced or metastatic disease
To send a Private Message to the Mods: community.breastcancer.org/mem...
Log in to post a reply

Page 1 of 1 (5 results)

Posts 1 - 5 (5 total)

Log in to post a reply

Jun 6, 2018 11:14AM b4uconsent wrote:

According to ClinicalTrials.gov, there are more than 600 studies actively enrolling in metastatic breast cancer. Can you tell us a little more about the process by which a study becomes "featured"? As of right now, the only featured study on the page linked is CONTESSA, sponsored by Odonate Therapeutics.

Log in to post a reply

Jun 11, 2018 12:46PM Moderators wrote:

Hi b4uconcent
We have seen positive audience participation with clinical trial matching tools on our site. To further raise awareness of clinical trials and encourage enrollment, especially around metastatic disease, we have created a new featured trial listing. The first of our sponsored clinical trials has been added with the goal of others following soon after. These listings, made possible through sponsorship, are evaluated by Breastcancer.org for their relevance to our breast cancer audience. As always we encourage you to talk to your doctor and make sure you know the benefits and risks associated with any clinical trial participation.

Thanks for asking, and we're working on making that page more clear.

The Mods

To send a Private Message to the Mods: community.breastcancer.org/mem...
Log in to post a reply

Jun 23, 2018 08:23AM b4uconsent wrote:

I saw that the language on the new trials page changed from "featured" to "sponsored" trials - a great change, and way more clear and appropriate. Thank you for working to raise the bar on transparency and put patients first.

Log in to post a reply

Aug 19, 2018 06:10PM Sarah1970 wrote:

You can’t get on this if you have previously tried Xeloda. F

Dx 7/2008, Right, 5cm, Stage IV, metastasized to brain/bone/liver/lungs, Grade 3, 8/24 nodes, ER+/PR-, HER2- Dx 2/2016, Right, Stage IV, metastasized to brain/bone/liver/lungs, PR+, HER2- Chemotherapy 2/22/2016 Abraxane (albumin-bound or nab-paclitaxel), Xeloda (capecitabine) Targeted Therapy Ibrance (palbociclib)
Log in to post a reply

Aug 19, 2018 06:20PM susan3 wrote:

to the moderators

Didn't know where to post this.

University of Chicago is on a phase II study of pembrolizumab and mifepristone with advanced stage HER 2 Negative breast cancer. They are also taking 25-34 hormone receptor positive.

They will get me in as soon as I am done with what's left on the table of treatments. Should be around the first of the year.

Hoping something else will come out that more specifically targets er positive.

Didn't read all the blogs on research. Sorry if you already posted about this.

Susa

Live and love fully Dx 3/2001, IDC, Stage IV, Grade 3, 40/5 nodes, ER+/PR-, HER2-

Page 1 of 1 (5 results)